Brian Liu

Dr. Liu is a Principal at Longitude Capital. Prior to joining Longitude Capital in 2018, Dr. Liu was an Engagement Manager in the pharmaceuticals and medical products practice of McKinsey & Company. Dr. Liu currently serves on the board of CG Oncology and is a board observer at Quanta Therapeutics, Rivus Pharmaceuticals, and Zenas Biopharma. He previously served as a board observer at Dascena, Endeavor Biomedicines, Inflazome (acquired by Roche), Talaris Therapeutics (TALS), and Vera Therapeutics (VERA), and was also actively involved in Longitude Capital’s investment in Strongbridge Biopharma (SBBP). Dr. Liu holds an MD from Stanford School of Medicine and a BS in Biomedical Engineering from The Johns Hopkins University.